On Wednesday, Amgen Inc announced that the U.S. FDA approved BKEMV (eculizumab-aeeb) injection, expanding its portfolio of rapid-acting, interchangeable products for the complement-mediated disorders market. Commercialization is set to begin this quarter, offering a flexible alternative to traditional treatments and positioning Amgen to defend its market share against biosimilar competition.